Biomarkers in bladder cancer
- PMID: 19793380
- DOI: 10.1111/j.1464-410X.2009.08880.x
Biomarkers in bladder cancer
Abstract
Detailed molecular insights into bladder cancer biology might allow more detailed prognostication and optimization of treatment with the objective of improving patient outcome and quality of life. However, in bladder cancer research the search for biomarkers has been called into question and has even obtained notoriety. It is unlikely that any single marker will be able to improve prognostication for patients with bladder cancer above and beyond grade and stage, but a combination of multiple independent markers might more precisely predict the outcome. From a previous review, we identified seven biomarkers to study within the setting of the Bladder Cancer Prognosis Programme (BCPP), a 5-year multicentre programme of research based at the University of Birmingham and funded by Cancer Research UK, investigating their effectiveness in predicting recurrence and progression. As part of the ongoing quality-assurance process for BCPP we present an updated review of our selected biomarkers, as well as highlighting other recent important developments in bladder cancer research.
Similar articles
-
Genetic and epigenetic aspects of bladder cancer.J Cell Biochem. 2005 May 1;95(1):24-33. doi: 10.1002/jcb.20412. J Cell Biochem. 2005. PMID: 15759278 Review.
-
P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.J Urol. 2007 Sep;178(3 Pt 1):1073-9. doi: 10.1016/j.juro.2007.05.012. Epub 2007 Jul 20. J Urol. 2007. PMID: 17644138
-
Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.J Urol. 2002 Jan;167(1):75-9. J Urol. 2002. PMID: 11743279
-
A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer.BJU Int. 2009 Dec;104(11):1780-5. doi: 10.1111/j.1464-410X.2009.08674.x. Epub 2009 Jun 12. BJU Int. 2009. PMID: 19522865
-
Urothelial cancer biomarkers for detection and surveillance.Urology. 2006 Mar;67(3 Suppl 1):25-33; discussion 33-4. doi: 10.1016/j.urology.2006.01.034. Urology. 2006. PMID: 16530072 Review.
Cited by
-
AMIGO2 expression at the invasive front of bladder cancer predicts recurrence-free and overall survival after radical cystectomy.Oncol Lett. 2025 May 13;30(1):339. doi: 10.3892/ol.2025.15085. eCollection 2025 Jul. Oncol Lett. 2025. PMID: 40421197 Free PMC article.
-
Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin.Urol Ann. 2011 Sep;3(3):119-26. doi: 10.4103/0974-7796.84954. Urol Ann. 2011. PMID: 21976923 Free PMC article.
-
Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.Philos Trans R Soc Lond B Biol Sci. 2015 Feb 5;370(1661):20140042. doi: 10.1098/rstb.2014.0042. Philos Trans R Soc Lond B Biol Sci. 2015. PMID: 25533099 Free PMC article. Review.
-
Metabolic profiling for the detection of bladder cancer.Curr Urol Rep. 2011 Feb;12(1):34-40. doi: 10.1007/s11934-010-0151-3. Curr Urol Rep. 2011. PMID: 21061098
-
Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors.Transl Androl Urol. 2018 Dec;7(Suppl 6):S715-S717. doi: 10.21037/tau.2018.10.09. Transl Androl Urol. 2018. PMID: 30687604 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials